These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 32749686)

  • 1. Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinoma.
    Hong MH; Heo SG; Lee YG; Kim HS; Park KU; Kim HG; Ko YH; Chung IJ; Min YJ; Kim MK; Kim KR; Yoo J; Kim TM; Kim HR; Cho BC
    Cancer; 2020 Oct; 126(20):4521-4531. PubMed ID: 32749686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical efficacy and identification of factors confer resistance to afatinib (tyrosine kinase inhibitor) in EGFR-overexpressing esophageal squamous cell carcinoma.
    Wang Y; Liu C; Chen H; Jiao X; Wang Y; Cao Y; Li J; Zhang X; Sun Y; Zhuo N; Dong F; Gao M; Wang F; Dong L; Gong J; Sun T; Zhu W; Zhang H; Shen L; Lu Z
    Signal Transduct Target Ther; 2024 Jun; 9(1):153. PubMed ID: 38937446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma.
    Kim HS; Kim SM; Kim H; Pyo KH; Sun JM; Ahn MJ; Park K; Keam B; Kwon NJ; Yun HJ; Kim HG; Chung IJ; Lee JS; Lee KH; Kim DJ; Lee CG; Hur J; Chung H; Park JC; Shin SK; Lee SK; Kim HR; Moon YW; Lee YC; Kim JH; Paik S; Cho BC
    Oncotarget; 2015 Dec; 6(42):44971-84. PubMed ID: 26462025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.
    Machiels JP; Haddad RI; Fayette J; Licitra LF; Tahara M; Vermorken JB; Clement PM; Gauler T; Cupissol D; Grau JJ; Guigay J; Caponigro F; de Castro G; de Souza Viana L; Keilholz U; Del Campo JM; Cong XJ; Ehrnrooth E; Cohen EE;
    Lancet Oncol; 2015 May; 16(5):583-94. PubMed ID: 25892145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy.
    Machiels JP; Licitra LF; Haddad RI; Tahara M; Cohen EE
    BMC Cancer; 2014 Jun; 14():473. PubMed ID: 24973959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant human endostatin plus paclitaxel/nedaplatin for recurrent or metastatic advanced esophageal squamous cell carcinoma: a prospective, single-arm, open-label, phase II study.
    Wang ZQ; Wang DS; Wang FH; Ren C; Tan Q; Li YH
    Invest New Drugs; 2021 Apr; 39(2):516-523. PubMed ID: 33070249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mouse avatar models of esophageal squamous cell carcinoma proved the potential for EGFR-TKI afatinib and uncovered Src family kinases involved in acquired resistance.
    Liu Z; Chen Z; Wang J; Zhang M; Li Z; Wang S; Dong B; Zhang C; Gao J; Shen L
    J Hematol Oncol; 2018 Aug; 11(1):109. PubMed ID: 30157900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial.
    Goss GD; Felip E; Cobo M; Lu S; Syrigos K; Lee KH; Göker E; Georgoulias V; Li W; Guclu S; Isla D; Min YJ; Morabito A; Ardizzoni A; Gadgeel SM; Fülöp A; Bühnemann C; Gibson N; Krämer N; Solca F; Cseh A; Ehrnrooth E; Soria JC
    JAMA Oncol; 2018 Sep; 4(9):1189-1197. PubMed ID: 29902295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 2 study of spartalizumab (PDR001) among patients with recurrent or metastatic esophageal squamous cell carcinoma (KCSG HN18-17, K-MASTER project 12).
    Lee DK; Park SR; Kim YH; Lee YG; Shin SJ; Ahn BC; Lee SS; Lim SM; Kim HR; Cho BC; Hong MH
    Oncoimmunology; 2024; 13(1):2371563. PubMed ID: 38919826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.
    Zhang B; Qi L; Wang X; Xu J; Liu Y; Mu L; Wang X; Bai L; Huang J
    Cancer Commun (Lond); 2020 Dec; 40(12):711-720. PubMed ID: 33314747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.
    Soria JC; Felip E; Cobo M; Lu S; Syrigos K; Lee KH; Göker E; Georgoulias V; Li W; Isla D; Guclu SZ; Morabito A; Min YJ; Ardizzoni A; Gadgeel SM; Wang B; Chand VK; Goss GD;
    Lancet Oncol; 2015 Aug; 16(8):897-907. PubMed ID: 26156651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Efficacy of Taxol Plus Platinum (TP) Chemotherapy Combined with Delayed Administration of PD-1 Inhibitors in Patients with Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma: A Retrospective Study.
    Shen L; Chen Z; Zhang Z; Wu Y; Ren Y; Li Y; Li Y; Yin X; Han F; Chen Y
    Drug Des Devel Ther; 2024; 18():2761-2773. PubMed ID: 38979399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole-exome sequencing reveals critical genes underlying metastasis in oesophageal squamous cell carcinoma.
    Dai W; Ko JMY; Choi SSA; Yu Z; Ning L; Zheng H; Gopalan V; Chan KT; Lee NP; Chan KW; Law SY; Lam AK; Lung ML
    J Pathol; 2017 Aug; 242(4):500-510. PubMed ID: 28608921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remarkable inhibition effects of afatinib alone or combining with paclitaxel in esophageal squamous cell carcinoma.
    Yang LY; Cheng ZJ; Liu Z; Wang D; Zhang N; Fan ZL; Cai HQ; Zhang Y; Cai Y; Xu X; Wang JH; Du GH; Hao JJ; Wang MR
    J Gastroenterol Hepatol; 2021 Sep; 36(9):2513-2522. PubMed ID: 33721913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Old Story Retold: Loss of G1 Control Defines A Distinct Genomic Subtype of Esophageal Squamous Cell Carcinoma.
    Wang Q; Bai J; Abliz A; Liu Y; Gong K; Li J; Shi W; Pan Y; Liu F; Lai S; Yang H; Lu C; Zhang L; Chen W; Xu R; Cai H; Ke Y; Zeng C
    Genomics Proteomics Bioinformatics; 2015 Aug; 13(4):258-70. PubMed ID: 26386145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402).
    Yokoyama T; Yoshioka H; Fujimoto D; Demura Y; Hirano K; Kawai T; Kagami R; Washio Y; Ishida T; Kogo M; Tomii K; Okuno T; Akai M; Hirabayashi M; Nishimura T; Nakahara Y; Kim YH; Miyakoshi C; Yoshimura K; Hirai T;
    Lung Cancer; 2019 Sep; 135():175-180. PubMed ID: 31446992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Larotinib in patients with advanced and previously treated esophageal squamous cell carcinoma with epidermal growth factor receptor overexpression or amplification: an open-label, multicenter phase 1b study.
    Liu R; Liu L; Zhao C; Bai Y; Zheng Y; Zhang S; Li N; Yang J; Fan Q; Wang X; Zeng S; Zhang Y; Zhang W; Zhuang Y; Kang N; Jiang Y; Sun H; Xu J
    BMC Gastroenterol; 2021 Oct; 21(1):398. PubMed ID: 34688250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Afatinib and Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (ALPHA Study): A Phase II Study with Biomarker Analysis.
    Kao HF; Liao BC; Huang YL; Huang HC; Chen CN; Chen TC; Hong YJ; Chan CY; Chia JS; Hong RL
    Clin Cancer Res; 2022 Apr; 28(8):1560-1571. PubMed ID: 35046059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer.
    Cohen EEW; Licitra LF; Burtness B; Fayette J; Gauler T; Clement PM; Grau JJ; Del Campo JM; Mailliez A; Haddad RI; Vermorken JB; Tahara M; Guigay J; Geoffrois L; Merlano MC; Dupuis N; Krämer N; Cong XJ; Gibson N; Solca F; Ehrnrooth E; Machiels JH
    Ann Oncol; 2017 Oct; 28(10):2526-2532. PubMed ID: 28961833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.